COVID-19 Testing

Employers are under more pressure than ever to protect the health and safety of their employees

Uncompromised on-site testing with the LumiraDx Platform delivers fast, accurate antigen testing. Rapidly identify potentially contagious spreaders on the spot, reducing the risk of a local outbreak & the potential impact on your operations, helping to build employee confidence

"It’s time to change how we think about the sensitivity of testing for COVID-19."1

The benefits of uncompromised on-site testing with LumiraDx

benefits of on-site testing with LumiraDx chartbenefits of on-site testing with LumiraDx chart
  • Less-sensitive lateral flow antigen tests2-4 increase the risk of an infectious employee getting a negative result.
    False negatives leave the door open for contagious persons to slip through (i.e., goes to work rather than flagged for isolation)
  • ‘Swab and send’ delays time needed to get to actionable results
  • PCR can remain positive up to 12 weeks after period of infectivity5

#Negative results do not rule out SARS-CoV-2 infection and should be considered in the context of an individual’s recent exposures, history and presence of clinical signs and symptoms consistent with COVID-19. Results should not be used as the sole basis for treatment or case management decisions, including infection control decisions
**Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status

SARS-CoV-2 Portfolio

Easy to implement on-site at point of care

  • Room Temperature Storage (2-30˚C)
  • Time to result in as quick as 12 minutes
  • Compact and portable instrument with connectivity options

High sensitivity Assay

  • Optimal sensitivity to rapidly detect potentially infectious individuals to prevent onward transmission

Bring the lab to you

  • No need to send employees off site
  • Get the data to inform your decisions on safety and reopening at a micro and macro level
  • COVID-19 testing dedicated to your specific needs

LumiraDx SARS-CoV-2 Ag Test

  • LumiraDx SARS-CoV-2 Ag Test demonstrates high sensitivity at Ct<336
  • LumiraDx SARS-CoV-2 Ag Test can detect 10-30% cases potentially missed by antigen lateral flow tests7-11
  • PCR can still be positive long after period of infectivity, leading to misidentification of infective individuals5
  • SARS-CoV-2 Ag correlates with culture better than PCR for aiding in the identification of infective individuals12
  • LumiraDx SARS-CoV-2 Ag Test provides high detection of potentially infective individuals to break the chain of transmission

Pool Test

  • Test up to 5 people using 1 test
  • Quickly and easily scale up testing: Low-cost diagnostic screening solutions
  • Maximize resources: Pooled testing can improve access to testing by significantly reducing resources (tests, operators, instruments) required on a per patient basis
  • Save Time and cost: Pooled testing can result in a savings in both time and cost
View Test Page

SARS-CoV-2 Ab Test

The LumiraDx SARS-CoV-2 Ab Test is designed to be used in point of care settings to identify individuals who have antibodies to SARS-CoV-2

The LumiraDx SARS-CoV-2 Ab assay identifies antibodies to two viral regions that are primary targets for neutralising antibodies.

Knowing the COVID-19 antibody status of a workplace may allow employers and organisers to mitigate risk and make better informed choices on both micro and macro levels.

View Test Page

LumiraDx Connect

  • LumiraDx Connect is an intelligent, integrated connectivity platform that uses the latest cloud-controlled technology for use with LumiraDx Instrument.
  • LumiraDx Connect ensures easy, secure transfer of results from LumiraDx Instrument to Connect Manager.
  • Can be used with mobile phones, tablets or PCs

We are focused on customer experience and dedicated to getting it right every time.

Inquire now

1: Michael J. Mina, etal., Rethinking Covid-19 Test Sensitivity — A Strategy for Containment, N Engl J Med 2020; 383:e120

2: Report of the „Bundesamt für Gesundheit“ Switzerland 2020 (available upon request)

3: Kohmer et al., 2021. J Clin Med Jan 17;10(2):328.

4: Krüger et al., 2021 (


6: Drain PK, Ampajwala M, Chappel C, et al. A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance Study. Infect Dis Ther. 2021;10(2):753-761.

7: Linares et al, Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms, J Clin Virol. 2020 Dec; 133: 104659

8: Gannon C.K. Mak, Stephen S.Y. Lau, Kitty K.Y. Wong, Nancy L.S. Chow, C.S. Lau, Edman T.K. Lam, Rickjason C.W. Chan, Dominic N.C. Tsang, Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2, Journal of Clinical Virology, Volume 134, 2021, 104712, ISSN 1386-6532,

9: Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, Griego-Fullbright C, Burgard C, Fernandez C, Eckert K, Andrews JC, Ren H, Allen J, Ackerman R, Cooper CK. 2021. Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-ofcare test. J Clin Microbiol 59:e02338-20. https://

10: Osterman, A., Baldauf, HM., Eletreby, M. et al. Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting. Med Microbiol Immunol 210, 65–72 (2021).

11. Labcorp EUA – Histogram of Cts,

12: Andrew Pekosz et al., Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture, Clinical Infectious Diseases, 2021;, ciaa1706,


Supporting healthier lives, for individuals, communities and wider society

Enabling responsive, personal relationships between patients and care teams.

Controlling and reducing costs to help ease pressure on healthcare budgets.